Tricuspid-Valve Intervention in Heart Failure.

Transcatheter tricuspid-valve repair significantly improves outcomes in patients with severe tricuspid regurgitation, with a win ratio of 2.42 favoring repair at 1 year.

• Why it matters: Severe tricuspid regurgitation is linked to high mortality and hospitalization rates, but the impact of repair procedures on these outcomes remains uncertain, highlighting a critical gap in treatment evidence.
• What they did: A randomized trial assigned 360 patients with symptomatic severe tricuspid regurgitation to either tricuspid-valve repair plus medical therapy or medical therapy alone, assessing primary endpoints over 1 to 3 years.
• The result: Tricuspid-valve repair reduced the risk of death or hospitalization for heart failure, with a 52.4% freedom from these events at 3 years compared to 21.0% in the medical group, and 5.9% experienced major adverse events within 30 days.